Scientific opinion on the tolerable upper intake level for vitamin E

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA),Dominique Turck,Torsten Bohn,Jacqueline Castenmiller,Stefaan de Henauw,Karen-Ildico Hirsch-Ernst,Helle Katrine Knutsen,Alexandre Maciuk,Inge Mangelsdorf,Harry J McArdle,Kristina Pentieva,Alfonso Siani,Frank Thies,Sophia Tsabouri,Marco Vinceti,Maret G Traber,Misha Vrolijk,Charlotte Marie Bercovici,Agnès de Sesmaisons Lecarré,Lucia Fabiani,Nena Karavasiloglou,Vânia Mendes,Silvia Valtueña Martínez,Androniki Naska

DOI: https://doi.org/10.2903/j.efsa.2024.8953

2024-08-02

Abstract:Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver a scientific opinion on the revision of the tolerable upper intake level (UL) for vitamin E. As α-tocopherol is recognised as the only essential form of vitamin E, the Panel restricted its evaluation to α-tocopherol. Systematic reviews of the literature were conducted to assess evidence on priority adverse health effects of excess intake of vitamin E, namely risk of impaired coagulation and bleeding, cardiovascular disease and prostate cancer. The effect on blood clotting and associated increased risk of bleeding is considered as the critical effect to establish an UL for vitamin E. No new evidence has been published that could improve the characterisation of a dose-response. The ULs for vitamin E from all dietary sources, which were previously established by the Scientific Committee on Food, are retained for all population groups, i.e. 300 mg/day for adults, including pregnant and lactating women, 100 mg/day for children aged 1-3 years, 120 mg/day for 4-6 years, 160 mg/day for 7-10 years, 220 mg/day for 11-14 years and 260 mg/day for 15-17 years. A UL of 50 mg/day is established for infants aged 4-6 months and a UL of 60 mg/day for infants aged 7-11 months. ULs apply to all stereoisomeric forms of α-tocopherol. ULs do not apply to individuals receiving anticoagulant or antiplatelet medications (e.g. aspirin), to patients on secondary prevention for CVD or to patients with vitamin K malabsorption syndromes. It is unlikely that the ULs for vitamin E are exceeded in European populations, except for regular users of food supplements containing high doses of vitamin E.